Cryo-Cell International, Inc. (CCEL)

ASE – Real Time Price. Currency in USD

3.41

-0.11 (-3.13%)

At close: May 12, 2026, 9:30 AM EDT

3.41

0.00 (0.00%)

After-hours: May 12, 2026, 5:05 PM EDT

08.05.2026

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced that the NYSE American LLC (the “NYSE American") has accepted the Company's previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, 2026, the Company was notified that it was not in compliance with Section 1003 (a) of the NYSE American Co.

28.04.2026

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT”) Accreditation for Cord Blood Collection, Banking, and Release for Administration (Related and Unrelated) Donations. Originally accredited in 2014, the Company's latest FACT re-accreditation extends for three more years, with the latest renewal effective through Ap.

14.04.2026

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2026. Financial Results Revenue The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first quarter of fiscal 2025. The revenues for the first quarter of fiscal 2026 consisted of $7.64 million i.

12.03.2026

Cryo-Cell Receives NYSE American Continued Listing Notice

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in com.

27.02.2026

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025. Financial Results Revenue Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue.

15.07.2025

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2025. Financial Results Revenue The revenues for the second quarter of fiscal 2025 were $7.9 million compared to $8.0 million for the second quarter of fiscal 2024, a 1% decrease. The revenues for the second quarter of fiscal 2025 consisted of $7.8.

Videos

No Data

There is no data to display

Press releases

08.05.2026

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

28.04.2026

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

14.04.2026

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2026. Financial Results Revenue The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first quarter of fiscal 2025. The revenues for the first quarter of fiscal 2026 consisted of $7.64 million i.

12.03.2026

Cryo-Cell Receives NYSE American Continued Listing Notice

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced that is has received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in com.

Cryo-Cell International, Inc. (CCEL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cryo-Cell International, Inc. (CCEL)

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

Cryo-Cell Receives NYSE American Continued Listing Notice

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results

Videos

No Data

Press releases

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

Cryo-Cell Receives NYSE American Continued Listing Notice

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

Cryo-Cell Receives NYSE American Continued Listing Notice

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results

Videos

No Data

Press releases

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

Cryo-Cell Receives NYSE American Continued Listing Notice

Search stocks

Cryo-Cell International, Inc. (CCEL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Cryo-Cell International, Inc. (CCEL)

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

Cryo-Cell Receives NYSE American Continued Listing Notice

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results

Videos

No Data

Press releases

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

Cryo-Cell Receives NYSE American Continued Listing Notice

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

Cryo-Cell Receives NYSE American Continued Listing Notice

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results

Videos

No Data

Press releases

Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

Cryo-Cell Receives NYSE American Continued Listing Notice